Putting Science to Work

Archives / 2018

  • Syngene International Q1 net profit up 6% at Rs 66 crore

    PharmaBiz- 26/07/2018. The quarter saw good performance within biologics manufacturing, discovery services and chemical development services as well as a benefit from improved FX rates.

    .

  • Syngene expands agreement with Baxter

    India Infoline- 23/07/2018. Syngene and Baxter originally established the Baxter Global Research Center in 2013. The duration of the new agreement has now been extended until 2024.

    .

  • Artelo Biosciences Enters Into Global R&D Partnership With Syngene International And Aptus Clinical For The Clinical Development Of ART27.13 In Oncology

    Cision PR Newswire- 12/06/2018. As part of the agreement, Syngene will be the discovery and development partner providing a pre-clinical data package to support the advancement of ART27.13 for anti-cancer indications.

    .

  • Syngene teams with immuno-oncology firm to provide greater value-added services

    Out Sourcing Pharma- 04/06/2018. As per the partnering agreement, Syngene will screen target antigens Zumutor’s human antibody libraries to identify and characterize novel antibody clones- which it will further develop towards novel biotherapeutics programs.

    .

  • An Exclusive Interview with Jonathan Hunt – CEO, Syngene International, India by Pharma Boardroom

    Pharma Boardroom- 24/05/2018. Syngene International, one of the fastest growing and leading contract research and manufacturing organizations in the world, discusses the company’s unique ecosystem of innovation...

    .

  • Syngene International Q4 net rises 8% to Rs 84 crore

    Money Control-25/04/2018. During FY18, the company's net profit increased by 6 percent at Rs 305 crore and revenue by 17 percent at Rs 1,485 crore.

    .

  • /Media/Default/images/infd.jpg
    Syngene enters pact with GSK to provide drug discovery services

    Money Control-27/03/2018. As part of the agreement, Syngene will set-up a customized discovery research laboratory to support projects across several therapeutic areas.

    .

  • /Media/Default/images/infd.jpg
    Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl

    Money Control-24/01/2018. With a focus on future business growth, the company has done lot of investments – building new infrastructure and capabilities and they are now ready, said Hunt...

    .

  • We are in the process of implementing a $200 million growth capex plan to expand capacity and extend capabilities

    Globally, we anticipate to see a healthy demand for high quality scientific services, not just in the pharma and biotechnology industries but also in other research focused industries...

    .

Discovery Chemistry Discovery Biology Safety Assessment Large Molecule Development Chemical Development Formulation Development Stability Studies Polymer Research Integrated Discovery & Development Clinical Development Services Bioinfomatics Antibody Drug Conjugates Oligonucleotide Synthesis Contact Us

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

Social Widget